BACE1 and early-onset autosomal dominant Alzheimer disease: Atabecestat, a potent brain penetrable BACE1 inhibitor that reduces CSF amyloid beta (Aβ), was developed by Janssen Research & Development LLC and Shionogi and Co Ltd as an oral treatment for Alzheimer’s disease (AD).